VEGFs (vascular endothelial growth factors) are master regulators of vascular development and of blood and lymphatic vessel function during health and disease in adults. This family of five mammalian ligands acts through three RTKs (receptor tyrosine kinases). In addition, co-receptors such as NRPs (neuropilins) associate with the ligand-receptor signalling complex and modulate the output. Therapeutics to block several of the VEGF signalling components as well as NRP function have been developed with the aim of halting blood vessel formation, angiogenesis, in diseases that involve tissue growth and inflammation, such as cancer. The present review outlines the current understanding of NRPs in relation to blood and lymphatic vessel biology.
Introduction
The mammalian VEGF (vascular endothelial growth factor) family consists of five homodimeric polypeptides of 40 kDa: VEGF-A, -B, -C and -D and PlGF (placental growth factor). VEGF-A is alternatively spliced to generate VEGF-A 121 , VEGF-A 145 , VEGF-A 165 and VEGF-A 189 , which are endowed with different biological properties [1] . The VEGFs bind with different affinities to three RTKs (receptor tyrosine kinases), VEGFR (VEGF receptor) 1, 2 and 3 [2] . VEGFR1 is critical in the regulation of migration of endothelial precursors as well as mature monocyte/macrophages. VEGFR2 is the key transducer of VEGF function in vascular ECs (endothelial cells), whereas VEGFR3 is required for lymphatic endothelial function. In addition, VEGFs bind to two NRP (neuropilin) homologues, NRP1 and NRP2, which modulate the biological outcome of VEGF/VEGFR-mediated signalling [3] .
VEGF is produced as a consequence of relative hypoxia in a growing tissue and mediates angiogenesis, i.e. the formation of new blood vessels, mainly through VEGFR2 and NRP1. Development of therapies that target the function of VEGFs and their receptors in treatment of diseases characterized by excess angiogenesis such as cancer and retinopathies, have promoted a vivid interest in understanding signal transduction regulating the angiogenic process. Increased understanding of VEGFR and NRP signal transduction in vivo is essential to further develop fine-tuned therapy to allow targeting of pathways critical in formation of vessels in pathological conditions, while preserving pathways required for survival of ECs in normal vessels.
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Expression of NRPs
The NRPs were first identified as receptors for class 3 semaphorins, a family of soluble molecules with neuronal guidance functions. Gene targeting as well as overexpression of NRPs have established their critical role in the development of both the nervous and the vascular systems [4] [5] [6] .
During development, NRP1 is preferentially expressed in arteries, and NRP2 is expressed in veins and lymphatics [7] [8] [9] . Both overexpression and disruption of NRP1 in mice lead to embryonic lethality at E (embryonic day) 12.5-13.5 due to either an excess of vessel formation or a range of vascular abnormalities respectively [10, 11] . NRP2-knockout mice show normal development of arteries and veins, but display marked defects in the development of capillaries and small lymphatics [9] . Consistently, NRP2 mediates VEGF-C-induced lymphatic sprouting in a VEGFR3-dependent manner [12] . NRP1/NRP2-double-knockout mice display a more severe phenotype and die in utero at E8.5 with a completely avascular yolk sac [13] .
NRPs are also expressed in many non-ECs such as smooth muscle cells [14] , neurons [15] , epithelial cells [16] and immune cells [17] . Many reports implicate NRPs in the regulation of migration of these different cell types (see below). Increased NRP expression in human leukaemia and lymphoma [18] and in many solid tumour types, is associated with increased metastasis [19] [20] [21] [22] [23] [24] . However, it remains to be shown which cell types in the tumour express NRPs. one transmembrane domain (amino acids 857-879) and a relatively short cytoplasmic tail (amino acids 880-923; 44 amino acids for NRP1 and 43 amino acids for NRP2), lacking intrinsic catalytic function [27] . The extracellular domains of both NRPs are divided further into the a1-a2 subdomain, which is homologous with components of the complement system and binds semaphorins; the b1-b2 subdomain, which shares homology with coagulation Factors V and VIII, binds VEGF-A and supports semaphorin binding to the a1-a2 domain; the c domain, which contains a MAM (meprin, A5/NRP, protein tyrosine phosphatase μ) domain and mediates NRP dimerization together with the transmembrane domain [26] . Between the NRPs, the a1-a2 domains share 45%, the b1-b2 domains 48% and the c-domains 35% amino acid sequence homology [28] . The most C-terminal three amino acids Ser-Glu-Ala, the so called SEA motif of NRP1, can bind PDZ domains of intracellular proteins such as synectin [also termed GAIP (G α -interacting protein)-interacting protein C-terminus or GIPC], which links NRP1 via myosin VI to the cytoskeleton and plays a role in internalization [29] (Figure 1A ). An important difference between the NRPs is that NRP1, but not NRP2, binds heparin/heparan sulfate via the b1-b2 subdomain [30] .
VEGF-A binding to NRPs
In addition to semaphorins, which bind NRPs with a K d of 0.8-1.15 nM (Sema3A to NRP1) [4, 31, 32] (Table 1) , NRPs are also receptors for VEGF ligands, but with different affinities ( Table 2 ). The electronegative potential in the b1-loop of NRPs seems to be critical for high-affinity VEGF binding [33] . Interestingly, NRP1 binds VEGF with an approximately 3-fold higher affinity than VEGFR2 (Table 2) . Furthermore, NPR1 additionally binds PlGF and VEGF-B, whereas NRP2 binds PlGF, VEGF-A 145 and VEGF-C [26] . In addition to binding specific ligands, the NRPs interact with different receptors, i.e. NRP1 is a co-receptor for VEGFR1/2, whereas NRP2 is a co-receptor for VEGFR3 [34, 35] . Moreover, NRP1 is modified, in a cell-type-specific manner, by heparan and chondroitin sulfation, which may determine the responsiveness to VEGF [36] and is crucial for invasiveness of tumours [37] . Soluble NRP1 and NRP2 isoforms may serve to sequester VEGF [26, 38] . Consistently, mice overexpressing soluble NRP1 show decreased VEGF-A-induced vascular permeability [26] .
The C-terminal domain of VEGF-A, especially amino acids 160-165 (exon 8-encoded), is required for binding to NRP [30] . In addition, the exon 7-encoded domain of VEGF-A is required for heparin binding [39] and forms, together with the heparin-binding region in the NRP molecule (the b1-b2 domain), one continuous heparinbinding surface, which may mediate complex formation with VEGFR2 via heparin and heparan sulfate [30] (Figure 1A) . VEGF-A isoforms lacking exon 7, like VEGF-A121, can still bind NRP1 via the exon 8-encoded C-terminal domain, but cannot mediate the heparin-dependent bridging between NRP1 and VEGFR2 [40] . The exact mechanism whereby NRP1 may enhance VEGF-A 121 -induced VEGFR2 activation [41] and how VEGF-A 121 heparin-dependently induces permeability in vivo, similar to VEGF-A 165 [42] , remains to be elucidated. VEGFs may also bind other RTKs; for example, in prostate cancer cells, VEGF-A activates c-Met signalling independently of HGF (hepatocyte growth factor), resulting in metastasis, and NRP1 may be crucial in this process [43] .
In addition to Sema3A, NRPs bind heparin-binding growth factors other than VEGFs, such as HGF, PDGF (platelet-derived growth factor)-BB, FGF (fibroblast growth factor) 2, TGFβ (transforming growth factor β) and Gal1 (galectin 1) [26] . It is not clear which domains of the NRPs mediate this binding; however, it was suggested that NRP1 contains a heparin-mimetic site, which may interact with heparin-binding domains of other proteins [44] .
NRP1 as a co-receptor for VEGF
VEGFR2 is considered to be the main mediator of VEGFinduced angiogenesis. However, considering the lethal phenotypes of NRP-knockout and NRP-overexpressing mouse models (described above), fine-tuned NRP expression in addition to VEGFR2 seems to be essential for blood vessel formation already very early in development.
At the cellular level, NRP1 expression leads to enhanced migration and survival of ECs in vitro [49, 50] . Furthermore, NRP1 has been implicated in VEGFR2-mediated permeability [51] . In particular, NRP1 has been shown to be essential in VEGF-A-induced three-dimensional biology, such as vessel sprouting and branching [3] .
One of the key questions concerning NRP biology is how their binding of VEGF ligands affects VEGF-induced signal transduction leading to sprouting angiogenesis. The exact molecular mechanisms through which NRP1 modulates VEGF biology remain to be elucidated. It has, however, been shown that NRP1 potentiates VEGF/VEGFR2 signalling, in particular, signalling pathways resulting in a migratory response [3] .
Different VEGF isoforms, with the capacity to bridge NRP1 and VEGFR2 or not, have been used as tools to show that only NRP1-binding VEGF isoforms are able to induce p38 MAPK (p38 mitogen-activated protein kinase) downstream of VEGFR2 and subsequent sprouting of vessels. This was enhanced further by VEGF isoforms that also bind heparin [3] . Therefore, for a full response to VEGF, a signalling complex is necessary that comprises at least VEGF, VEGFR2, NRP1 and heparin or HSPG (heparan sulfate proteoglycan) ( Figure 1A ). The cytoplasmic domain of NRP1 may be important for this complex formation [52] . NRP1 has also been implicated in intracellular trafficking of VEGFR2 by association of the NRP1 C-terminal SEA motif to the PDZ domain of the adaptor synectin (GIPC) [29] .
It remains to be shown whether NRP1 transduces VEGF signals independently of VEGFR2 through its C-terminal PDZ-binding domain, or whether it modulates VEGFR2 signalling, e.g. by influencing the tertiary structure of the receptor or the stability of the signalling complex.
NRP1 as a co-receptor of other growth factors
NRP1 serves as a co-receptor not only for VEGFs, but also for other ligands. For example, NRP1 physically binds the RTK c-Met, and potentiates autocrine HGF-induced c-Met activation, leading to increased proliferation, survival and migration of TCs (tumour cells) in human glioma and pancreatic cancer [53] (Figure 1C) . In breast cancer cells, [48] NRP1 is a co-receptor for TGFβR (TGFβ receptor) and potentiates TGFβ-induced migration [54] ( Figure 1D ). PDGF/PDGFRα (PDGF receptor α)-induced VSMC (vascular smooth muscle cell) migration depends on NRP1 and is mediated via p130
Cas [53] . In particular, in HSCs (hepatic stellate cells), NRP1 potentiates PDGF/PDGFRmediated migration via c-Abl and Rac1 [55] (Figure 1E) .
In ECs, NRP1 potentiates the proliferative activity of FGF2 [44] ; however, the exact mechanism remains to be elucidated. The lectin Gal1 can also bind NRP1 on ECs via its carbohydrate-recognition domain. Gal1/NRP1 potentiate VEGF/VEGFR2-induced migration through the SAPK1 (stress-activated protein kinase 1)/JNK (c-Jun N-terminal kinase) pathway ( Figure 1B) . Interestingly, Gal1 expression in TAVECs (tumour-associated vascular ECs) is, similarly to NRP1 expression, crucial for tumour angiogenesis, is associated with progression of many tumour types and mediates the adhesion of TCs to ECs [56] .
NRP1 as a drug target and biomarker
Normally, a capillary or small vessel consists of ECs forming a tube. They are surrounded by a continuous basal membrane. In addition, VSMCs, so-called pericytes, stabilize the vessel and promote vessel maturation. However, when TCs in the vicinity of an existing vessel start to proliferate and secret VEGF, ECs initiate formation of sprouts in the direction of the VEGF-producing tumour. With increasing size, the tumour tissue gradually becomes hypoxic, which stimulates VEGF-dependent ingrowth of vessels that provide oxygen and nutrients. A wide range of immune and inflammatory cells are recruited that may further stimulate vessel ingrowth. Owing to the continuous production of pro-angiogenic growth factors, the tumour vasculature fails to mature and displays a discontinuous basal membrane and decreased pericyte coverage, poor perfusion and elevated permeability.
Since 1971, when Judah Folkman proposed the block of angiogenesis as an effective therapy for all types of cancer, many compounds with anti-angiogenic activity have been described, but only drugs targeting VEGF ligands or their cognate receptors confirm the encouraging pre-clinical results in the clinic (reviewed in [57] ). An additional challenge in the clinic is that stringent angiogenesis inhibition may promote metastatic spread. Therefore the novel approach is to correct the abnormal structure and functionality of tumour vessels and render them more accessible for the delivery of chemotherapeutic drugs. For example, targeting VEGF-A signalling induces a 'transient normalization' of the tumour vasculature in various tumour models.
Blocking VEGF-A using bevacizumab (an anti-VEGF antibody) increases NRP1 expression in cancer cells and tumour infiltration of CD68 + TAMs (tumour-associated macrophages) in rectal carcinoma patients. Thus, when inhibiting VEGF-A, blocking NRP1 may be necessary to prevent potential compensatory escape mechanisms. Indeed, targeting NRP1 in various ways decreases tumour angiogenesis and growth and normalizes vessels in the tumour in pre-clinical models. Notably, blocking NRP1 has an additive effect with anti-VEGF-A antibody treatment in reducing tumour growth and tumour vessel organization [58] .
Consistently, a neutralizing anti-NRP2 antibody reduces lymphangiogenesis and functional lymphatics in tumours, while leaving established lymphatics unaffected, and is accompanied by reduced metastatic spread [59] .
Until now, there has been no consensus biomarker for the prediction of responsiveness to anti-angiogenic cancer therapy. However, several are being studied, including systemic parameters (i.e. systemic blood pressure), genotypic parameters (VEGF polymorphisms), tissue markers (tumour microvessel density) and MRI (magnetic resonance imaging) parameters. Although the NRPs are still being evaluated, more and more data indicate their potential as biomarkers. For example, increased expression of NRP1 and/or NRP2 in human tumours in general correlates with tumour growth, tumour angiogenesis and invasiveness. Moreover, NRP1, but not NRP2, is suggested to be a prognostic marker in colon cancer. Preserved NRP1 expression in tumour tissue (compared with non-neoplastic tissue) indicates a better prognosis [57] .
Conclusions
NRPs are signalling mediators acting as co-receptors for VEGFRs and other RTKs (c-Met, PDGFR) with binding sites for multiple ligands (HGF, PDGF, FGF, TGFβ and Gal1). The NRPs can also, depending on the cellular context, mediate cell-cell contacts and cell-matrix interactions independently of ligand activation, resulting in cell adhesion (attraction and repulsion). NRP1 is a key molecule in the development of the vascular and neuronal systems and in diseases characterized by excessive vascularization, such as cancer. Therefore increased understanding of NRP biology and the development of NRPs as biomarkers and drug targets may help us to solve current challenges in cancer therapy, such as resistance and metastasis.
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